The market rally stumbled ahead of the Fed meeting. Amazon and AI plays Super Micro and AMD reported earnings late.
The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' INGREZZA drug to treat movement disorders associated with Huntington's disease, the company said on Tuesday. Huntington's disease is an inherited condition that causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability. INGREZZA was first approved in 2017 in its oral capsule formulation to treat adults with movement disorders tardive dyskinesia and chorea.
Q1 2024 Performance Highlighted by Growth in Net Income and Strategic Share Repurchases